By Bruce Jancin | Skin & Allergy News – Oct, 2008
“The overall message of our study is that as a clinician you don’t have to screen your patients with newly diagnosed [anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis] for any underlying cancer on a routine basis,” Dr. Mikkel Faurschou said at the annual congress of the European League Against Rheumatism.
See the rest of the article here.
What I have to say: It is very interesting that clinicians don’t think ANCA Vasculitis patients need cancer screening. In my experience, there has been kidney cancer from WG patients after using cychlophosphamide. Plus I had a breast tumor that turned out to be benign, while I was taking WG treatment. So there are cases of cancer that do happen to Vasculitis patients. We can be grateful that it is not as common across the Vasculitis spectrum.